Separation Agreement between CytomX Therapeutics, Inc. and Jeffrey Landau
This agreement is between CytomX Therapeutics, Inc. and Jeffrey Landau, whose employment ended on February 7, 2025. It outlines the terms of Landau’s departure, including payment of accrued salary, a lump-sum severance of $450,657, COBRA healthcare premium coverage for up to 12 months, and the treatment of stock options. Landau agrees to release the company from future claims and acknowledges that this agreement supersedes prior employment-related agreements, except for confidentiality and stock option agreements. The agreement becomes effective eight days after signing, unless revoked.
Exhibit 10.1
SEPARATION AGREEMENT
This Separation Agreement (the “Agreement”) by and between Jeffrey Landau (“Executive”), and CytomX Therapeutics, Inc., a Delaware corporation (the “Company”), is made effective as of the eighth (8th) day following the date Executive signs this Agreement if not revoked in accordance with Section 5(c)(iii) (the “Effective Date”) with reference to the following facts:
A. Executive’s employment with the Company and status as an officer and employee of the Company and each of its affiliates ended effective as of February 7, 2025 (the “Termination Date”).
B. Executive and the Company are parties to that certain Amended and Restated Severance and Change of Control Agreement dated as of April 12, 2021, as amended (the “Severance Agreement”).
C. Executive and the Company want to end their relationship amicably and also to establish the obligations of the parties including, without limitation, all amounts due and owing to the Executive.
NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, the parties agree as follows:
1
|US-DOCS ###-###-####.1||
2
|US-DOCS ###-###-####.1||
3
|US-DOCS ###-###-####.1||
4
|US-DOCS ###-###-####.1||
BEING AWARE OF SAID CODE SECTION, EXECUTIVE HEREBY EXPRESSLY WAIVES ANY RIGHTS EXECUTIVE MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.
5
|US-DOCS ###-###-####.1||
6
|US-DOCS ###-###-####.1||
(Signature page(s) follow)
7
|US-DOCS ###-###-####.1||
IN WITNESS WHEREOF, the undersigned have caused this Separation Agreement to be duly executed and delivered as of the date indicated next to their respective signatures below.
DATED: 2/10/2025 /s/ Jeffrey Landau
__________________________________
Jeffrey Landau
CYTOMX THERAPEUTICS, INC.
DATED: 2/10/2025
/s/ Lloyd Rowland
By: _______________________________
Name: Lloyd Rowland
Title: SVP, General Counsel and Chief Compliance Officer
[Signature page to Separation Agreement]